Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015;11(3):680-1.
doi: 10.1080/21645515.2015.1011960.

Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia

J Kochanowski  1 , M Sobieszczańska, S Tubek, M Żurek, J Pawełczak
Affiliations
Case Reports

Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia

J Kochanowski et al. Hum Vaccin Immunother. 2015.

Abstract

Hereditary hemorrhagic telangiectasia (HHT), genetic disorder manifested by uncontrolled multisystem angiogenesis with epistaxis, gastrointestinal bleeding, iron-deficiency anaemia, and arteriovenous malformations (AVM) is often related with increased levels of vascular endothelial growth factor (VEGF). Bevacizumab, a VEGF inhibitor, reduces epistaxis, telangiectasias, and iron-deficiency anaemia. A case of a female patient with HHT and chronic gastrointestinal bleeding is presented. The patient required iron supplementation and multiple blood transfusions. Bevacizumab brought marked symptomatic improvement and allowed for transfusion-independence. It is intended to apply for approval of the indications for bevacizumab administration in HHT as the 'orphan drug'.

Keywords: arteriovenosous malformations; bevacizumab; dosing; epistaxis; hereditary hemorrhagic telangiectasia (HHT); vascular endothelial growth factor (VEGF).

PubMed Disclaimer

References

    1. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (rendu-osler-weber syndrome). Am J Med Genet 2000; 91:66-67; PMID:10751092 - PubMed
    1. Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, et al. . Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012. Mar 7; 307(9):948-55; PMID:22396517; http://dx.doi.org/10.1001/jama.2012.250 - DOI - PubMed
    1. Epperla N, Hocking W. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res 2014. Mar 25. [Epub ahead of print]; PMID:24667223 - PMC - PubMed
    1. Kanellopoulou T, Alexopoulou A. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Expert Opin Biol Ther 2013. Sep; 13(9):1315-23; Epub 2013 Jul 2; PMID:23815519; http://dx.doi.org/10.1517/14712598.2013.813478 - DOI - PubMed
    1. Cirulli A, Liso A, D'Ovidio F, Mestice A, Pasculli G, Gallitelli M, Rizzi R, Specchia G, Sabbà C. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003; 110(1):29-32; PMID:12975554; http://dx.doi.org/10.1159/000072411 - DOI - PubMed

Publication types

LinkOut - more resources